Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 430.2 DKK 1.94% Market Closed
Market Cap: 30.6B DKK

EV/EBITDA
Enterprise Value to EBITDA

-16.2
Current
-18
Median
3.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-16.2
=
Enterprise Value
22.2B DKK
/
EBITDA
-1.4B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 15.4
Negative Multiple: -16.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 865.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -631.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
300.7
2-Years Forward
EV/EBITDA
-107.3
3-Years Forward
EV/EBITDA
-44.8